Chhanda Charan Danta
Recent advances in drug discovery for diabetic kidney disease
Danta, Chhanda Charan; Boa, Andrew N.; Bhandari, Sunil; Sathyapalan, Thozhukat; Xu, Shang Zhong
Authors
Dr Andrew Boa A.N.Boa@hull.ac.uk
Senior Lecturer
Sunil Bhandari
Professor Thozhukat Sathyapalan T.Sathyapalan@hull.ac.uk
Professor
Shang Zhong Xu
Abstract
Introduction: Diabetic kidney disease (DKD) is a leading cause of end-stage renal disease (ESRD), and 40% of patients with diabetes develop DKD. Although some pathophysiological mechanisms and drug targets of DKD have been described, the effectiveness or clinical usefulness of such treatment has not been well validated. Therefore, searching for new targets and potential therapeutic candidates has become an emerging research area. Areas covered: The pathophysiological mechanisms, new drug targets and potential therapeutic compounds for DKD are addressed in this review. Expert opinion: Although preclinical and clinical evidence has shown some positive results for controlling DKD progression, treatment regimens have not been well developed to reduce the mortality in patients with DKD globally. Therefore, the discovery of new therapeutic targets and effective target-based drugs to achieve better and safe treatment are urgently required. Preclinical screening and clinical trials for such drugs are needed.
Citation
Danta, C. C., Boa, A. N., Bhandari, S., Sathyapalan, T., & Xu, S. Z. (in press). Recent advances in drug discovery for diabetic kidney disease. Expert Opinion on Drug Discovery, https://doi.org/10.1080/17460441.2021.1832077
Journal Article Type | Review |
---|---|
Acceptance Date | Sep 30, 2020 |
Online Publication Date | Oct 28, 2020 |
Deposit Date | Dec 16, 2020 |
Publicly Available Date | Oct 27, 2022 |
Journal | Expert Opinion on Drug Discovery |
Print ISSN | 1746-0441 |
Electronic ISSN | 1746-045X |
Publisher | Taylor and Francis |
Peer Reviewed | Peer Reviewed |
DOI | https://doi.org/10.1080/17460441.2021.1832077 |
Keywords | Diabetic complications; Diabetic nephropathy; Drug discovery; Endothelin receptor blockers; Oxidative stress; Renin-angiotensin-aldosterone system; SGLT-2 inhibitors |
Public URL | https://hull-repository.worktribe.com/output/3650013 |
Publisher URL | https://www.tandfonline.com/doi/abs/10.1080/17460441.2021.1832077?journalCode=iedc20 |
Files
Article
(732 Kb)
PDF
Copyright Statement
©2020 University of Hull
You might also like
Salivary testosterone measurement in women with and without polycystic ovary syndrome
(2017)
Journal Article
Aspartame sensitivity? : a double blind randomised crossover study
(2015)
Journal Article